Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of rilzabrutinib in adults with primary warm autoimmune hemolytic anemia
MOH_2025-05-25_014096Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rilzabrutinib in warm autoimmune hemolytic anemia (wAIHA) (3 arms), sponsored by Sanofi. Primary endpoint: Durable hemoglobin response. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
rilzabrutinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on MOH_2025-05-25_014096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-25_014096.